MTB 004
Alternative Names: MTB-004Latest Information Update: 01 Feb 2023
Price :
$50 *
At a glance
- Originator MedTherapy
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 12 Jan 2023 MedTherapy and its partner company has patent pending application covering CAR-T technology (MedTherapy pipeline, January 2023)
- 12 Jan 2023 Early research in Haematological malignancies in USA (Parenteral) before January 2023 (MedTherapy pipeline, January 2023)